This is a routine continuation of existing non-dilutive NIH funding. Monitor upcoming clinical data readouts for CNM-Au8 in ALS and any updates on regulatory pathway discussions, which are the primary catalysts for the stock.
Price Chart
Executive Summary
Clene Inc. entered into a subaward amendment with NYU Grossman School of Medicine for the fourth year of its NIH grant, providing up to $7.2 million in additional funding for the CNM-Au8 Expanded Access Program in ALS. The total funds obligated to date under this subaward are $15.3 million. This is a routine continuation of existing non-dilutive funding and does not represent a material change in the company's outlook.
Key Facts
- Clene entered a subaward amendment with NYU for the fourth year of the NIH grant, effective October 15, 2026.
- Additional funding of $7,214,420 is obligated for the period September 1, 2026 to August 31, 2027.
- Total funds obligated to date under this subaward are $15,258,081.
- The NIH grant supports an Expanded Access Program for CNM-Au8 treatment of ALS under the Accelerating Access to Critical Therapies for ALS Act.
- The original four-year $45.1 million NIH grant was announced on October 5, 2023.
Financial Impact
Up to $7.2 million in additional non-dilutive grant funding for the fourth year of the ALS Expanded Access Program; total subaward obligations now $15.3 million.
Risk Factors
- NIH grant funding is subject to annual appropriations and compliance with grant terms.
- The Expanded Access Program does not directly lead to regulatory approval or commercialization.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032960 |
| Document: clnn20261012_8k.htm | 0001437749-26-032960 |
| Document: 0001437749-26-032960-index-headers.html | 0001437749-26-032960 |
| Document: 0001437749-26-032960-index.html | 0001437749-26-032960 |
| Document: 0001437749-26-032960.txt | 0001437749-26-032960 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 8-K | $3.73 | awaiting T+20 | — | $3.78 (+1.34%) |
Oct 19, 2026 7d ago | 8-K | $3.29 | awaiting T+20 | — | $3.78 (+14.89%) |
Oct 19, 2026 7d ago | Press Release | $3.29 | awaiting T+20 | — | $3.78 (+14.89%) |
Oct 13, 2026 12d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.78 (+11.50%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.78 (+8.92%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.78 (+2.07%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.78 (−8.70%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.78 (−8.70%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.78 (−26.74%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.78 (−46.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers